Sunesis Pharmaceuticals, Inc. (SNSS) Release: Vosaroxin Review Published in Expert Opinion on Investigational Drugs
7/24/2012 9:25:21 AM
SOUTH SAN FRANCISCO, Calif., July 24, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of a peer-reviewed paper in the August 2012 issue of Expert Opinion on Investigational Drugs (Volume 21, Number 8) featuring vosaroxin, the Company's lead product candidate currently being evaluated in a Phase 3 trial, the VALOR trial, for the treatment of relapsed or refractory acute myeloid leukemia (AML). The paper, titled "Vosaroxin: a novel antineoplastic quinolone," was written by Jonathan Abbas, MD, and Robert Stuart, MD, of the Medical University of South Carolina, Hollings Cancer Center. The paper provides an in-depth review of the development history of vosaroxin, its mechanism of action, pharmacology, metabolism, as well as preclinical and clinical data to date, and is available online at http://informahealthcare.com/doi/pdf/10.1517/13543784.2012.699038.